ストックスクリーナーアプリを入手
1.41
6.62%
-0.10
前日終値:
$1.51
開ける：
$1.47
24時間の取引高:
154.30K
Relative Volume:
0.09
時価総額：
$50.60M
収益：
$317.00K
当期純損益:
$-53.47M
株価収益率:
-0.746
EPS:
-1.89
ネットキャッシュフロー:
$-49.31M
1週間 パフォーマンス:
-14.02%
1か月 パフォーマンス:
-4.73%
6か月 パフォーマンス:
-42.91%
1年 パフォーマンス:
-40.00%
1日の値動き範囲:
$1.40
$1.4954
1週間の範囲:
$1.40
$1.6598
52週間の値動き範囲:
$1.00
$3.83
Immuneering Corp Stock (IMRX) Company Profile
名前
Immuneering Corp
セクター
電話
617-500-8080
住所
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
IMRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
1.41 | 50.60M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-13 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | ダウングレード | Jefferies | Buy → Hold |
| 2024-03-15 | 繰り返されました | Needham | Buy |
| 2024-03-15 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | 開始されました | Needham | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-04-19 | アップグレード | Mizuho | Neutral → Buy |
| 2023-04-19 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | 開始されました | Mizuho | Neutral |
| 2023-02-03 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | 開始されました | Chardan Capital Markets | Buy |
| 2022-04-01 | 開始されました | Oppenheimer | Outperform |
| 2022-01-07 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Immuneering Corp (IMRX) 最新ニュース
Immuneering Co. (NASDAQ:IMRX) Shares Bought by HighTower Advisors LLC - Defense World
Full Executive Team Reveals Next Growth Phase at Major Healthcare Conference - Stock Titan
Chardan Capital Weighs in on Immuneering FY2025 Earnings - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Immuneering (NASDAQ:IMRX) - Defense World
Immuneering Corp. Reports Promising Cancer Trial Results - TipRanks
Immuneering Strengthens Leadership: New CMO Joins with $212K Stock Option Grant - StockTitan
Immuneering reports Q4 EPS (58c), consensus (44c) - TipRanks
Immuneering Corp SEC 10-K Report - TradingView
Immuneering Corporation Q4 Net Income USD 18.1 Million -March 20, 2025 at 04:54 pm EDT - Marketscreener.com
Immuneering Breakthrough: New Cancer Drug Doubles Standard Treatment Success Rate - StockTitan
Immuneering appoints Igor Matushansky as CMO - The Pharma Letter
Immuneering appoints new Chief Medical Officer - Investing.com
Former Ipsen Executive Who Led FDA-Approved Cancer Drug Joins Immuneering as CMO - Stock Titan
Immuneering Slides As Insider Purchases Lose Another US$186k - Yahoo Finance
Brokerages Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.20 - Armenian Reporter
Immuneering Co. (NASDAQ:IMRX) Receives $12.20 Consensus PT from Analysts - Defense World
Immuneering (IMRX) Expected to Announce Quarterly Earnings on Friday - Defense World
Alkermes (NASDAQ:ALKS) & Immuneering (NASDAQ:IMRX) Head to Head Contrast - Armenian Reporter
Needham & Company LLC Reaffirms "Buy" Rating for Immuneering (NASDAQ:IMRX) - MarketBeat
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Immuneering and Regeneron partner on lung cancer trial - MSN
Immuneering and Regeneron partner on lung cancer trial By Investing.com - Investing.com UK
Immuneering Partners with Regeneron to Test Novel Cancer Drug Combination for NSCLC | IMRX Stock News - StockTitan
Analysts Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.80 - Defense World
Immuneering Co. (NASDAQ:IMRX) Sees Large Decrease in Short Interest - MarketBeat
Immuneering Corporation Unveils Promising Data for IMM-1-104 in Pancreatic Cancer, Plans for Expansion - HPBL
Immuneering Corporation Shares Jump 55% Following Breakthrough Pancreatic Cancer Trial Results - HPBL
Immuneering Leads The Pack Of 3 US Penny Stocks To Consider - Simply Wall St
Immuneering Co. (NASDAQ:IMRX) Short Interest Update - Defense World
Immuneering Corporation Stock Soars Following Promising Updates from Phase 2a Pancreatic Cancer Trials - HPBL
Short Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 23.1% - MarketBeat
Immuneering Reports Positive Phase 2a Data for IMM-1-104 in Pancreatic Cancer, Expands Trial Plans - HPBL
Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Immuneering reports progress in pancreatic cancer trial - Investing.com
Immuneering's (IMRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer - Markets Insider
Immuneering's Cancer Drug Shows 50% Response Rate in Phase 2a Pancreatic Cancer Trial, Beating Benchmark - Stock Titan
Geode Capital Management LLC Sells 12,160 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World
Analysts Set Immuneering Co. (NASDAQ:IMRX) PT at $12.80 - Defense World
Immuneering (NASDAQ:IMRX) Earns Buy Rating from Chardan Capital - Defense World
Immuneering’s (IMRX) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
3 Penny Stocks to Watch Now, 1/9/25 - TipRanks
Immuneering (NASDAQ:IMRX) Given "Buy" Rating at Chardan Capital - MarketBeat
Immuneering reports promising mid-stage readout for pancreatic cancer therapy - FirstWord Pharma
Wall Street-Heavily Traded - WDRB
Immuneering announce data update from Phase 2a trial of IMM-1-104 - TipRanks
Immuneering's (IMRX) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Why Is Immuneering Stock Trading Higher On Tuesday? - AOL
Immuneering touts positive pancreatic cancer data for MEK inhibitor - Endpoints News
Exciting Cancer Therapy Breakthrough! Immuneering’s New Trial Results Amaze - elblog.pl
Immuneering Corp (IMRX) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):